-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The link between celiac disease (CeD) and inflammatory bowel disease (IBD) is controversial.
recently conducted a systematic review and meta-analysis to assess the evidence of ceD and IBD association.
researchers collected database data, including MEDLINE, EMBASE, CENTRAL, Web of Science, CINAHL, DARE, and SIGLE, as of June 25, 2019, to assess the risk of CeD in IBD patients and IBD risk in CED patients, and compared it with any type of control group.
9791 studies, 65 of which were included in this meta-analysis.
there was moderate certainty that IBD patients had an increased risk of CeD (risk ratio of 3.96) compared to the control group, while patients with CeD had an increased risk of IBD (RR:9.88) compared to the control group.
evidence of low certainty increased the positive risk of anti-yeast antibodies (serological markers of IBD) in CeD patients (RR:6.22) compared to the control group.
that there was low determinative evidence that HLA-DQ2 or DQ8 in IBD patients had no significant abnormalities (RR:1.04) compared to the control group.
IBD patients had a lower level of evidence of increased risk of anti-tissue glutamine transamine enzymes (RR:1.52) compared to the control group.
IBD patients had a lower risk of anti-in-muscle antibody abnormalities (RR 0.70) than in the control group.
systematic review and meta-analysis showed a link between celiac disease and inflammatory bowel disease, with an increased risk of developing one disease.
.